Literature DB >> 2678682

Transrectal ultrasound for staging prior to radical prostatectomy.

S W Hardeman1, J Q Causey, D P Hickey, M S Soloway.   

Abstract

Transrectal ultrasound (TRUS) was used to predict tumor stage in 43 patients prior to radical prostatectomy. For assessing extracapsular extension, the sensitivity was 54 percent, specificity 58 percent, and accuracy 56 percent. For detecting seminal vesicle involvement, the sensitivity was 60 percent, specificity 89 percent, and accuracy 82 percent. The predominant tumor echo pattern was isoechoic in 37 percent of cases, mixed (hyper-, iso-, and hypoechoic) in 47 percent, and hypoechoic in 16 percent. An anterior-posterior to transverse dimension ratio of greater than 0.8 suggested diffuse involvement of the prostate with an increased chance of extracapsular spread.

Entities:  

Mesh:

Year:  1989        PMID: 2678682     DOI: 10.1016/0090-4295(89)90367-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  Three dimensional ultrasound and prostate cancer.

Authors:  S S Mehta; A R Azzouzi; F C Hamdy
Journal:  World J Urol       Date:  2004-11-12       Impact factor: 4.226

2.  Computer-assisted analysis of transrectal ultrasound images.

Authors:  B L Craine; G Oldani; J R Engel; R F Whitney; D Wright; E R Craine
Journal:  J Digit Imaging       Date:  1990-11       Impact factor: 4.056

Review 3.  Optimal cost-effective staging evaluations in prostate cancer.

Authors:  Gregory L Lacy; Douglas W Soderdahl; Javier Hernandez
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

4.  Imaging in the diagnosis and management of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2004

Review 5.  Ultrasound findings are not useful for defining stage T1c prostate cancer.

Authors:  H Sanders; R el-Galley
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

6.  [Imaging procedures to diagnose prostate cancer].

Authors:  M Seitz; B Scher; M Scherr; D Tilki; B Schlenker; C Gratzke; A Schipf; P Stanislaus; U Müller-Lisse; O Reich; C Stief
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.